Triggering Oocyte Maturation in POSEIDON Group 3 and 4 Poor Responders Using Double Trigger or HCG Trigger

ConditionInfertility
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorBedaya Hospital

About this trial

The aim of this randomized controlled study is to compare the efficacy of double trigger protocol \[ the co-administration of GnRH agonist with HCG ( 38 - 39 and 35 - 36 h prior to ovum pick-up, respectively \] with HCG in triggering ovulation in patients with expected poor response to ovarian stimulation

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

POSEIDON group 3 and 4

GnRH antagonist IVF cycle

Disqualifiers

Hypogonadotrophic hypogonadism

Endometriosis

History of recurrent abortion

Trial design

Design model

Parallel

Treatments tested in this trial

  • Double trigger

    Drug

    Triptorelin (0.2 mg/S.C ) and HCG (10000 IU/I.M) are administered 38 to 39 h and 35 to 36 h prior to ovum pick-up., respectively.

  • HCG trigger

    Drug

    HCG (10000 IU/I.M) is administered 35 to 36 h prior to ovum pick-up.

Treatment groups

164 Participants
are divided into 2 treatment groups
Group A: Double triggerExperimental treatment 1 intervention
Group B: HCG triggerActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Metaphase-II oocytes rate

Number of MII oocyte/ number of cumulus oocyte complex

Time frame
Ten to fifteen days after starting ovarian stimulation

Secondary outcomes

1

Clinical pregnancy rate

Presence of intrauterine gestational sac detected by transvaginal ultrasound

Time frame
Five weeks after embryo transfer
2

Ongoing pregnancy Rate

Pregnancies continued beyond 20 weeks gestation

Time frame
Eighteen weeks after embryo transfer

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: